About Us
Transforming Antibody Therapeutics
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people’s lives.
Our cross functional teams use a battery of intellectual property and an integrated platform of antibody technologies and capabilities to engineer cutting-edge therapeutic antibodies.
Pioneering New Products
Our flagship product candidate, XOMA 052, is an anti-inflammatory antibody with the potential to treat diseases like diabetes by addressing disease mechanisms in unexpected – and potentially more powerful – new ways. Other drug candidates in our pipeline include biodefense agents designed to protect against natural, accidental or intentional human exposure to botulism. Through collaborations with major biopharmaceutical partners, we are developing additional antibodies with multi-indication potential. XOMA 629, a topical antibacterial gel, is being evaluated for the eradication Staphylococcus aureus and the treatment of impetigo.
A Trusted Partner
Global biotechnology and pharmaceutical companies turn to XOMA for our valued antibody technologies and capabilities. Licensing and development collaborations have yielded three XOMA-enabled products that have received marketing approval and provide XOMA with royalty revenues. XOMA also generates revenue by licensing its antibody technologies and libraries.
